Posted by Michael Wonder on 27 Mar 2024
Truqap plus Faslodex approved in Japan for patients with advanced HR positive breast cancer
27 March 2024 - Approval based on CAPItello-291 results which showed Truqap plus Faslodex reduced the risk of disease progression or death by 50% versus Faslodex alone in the biomarker-altered population
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor positive, HER2 negative breast cancer following progression after treatment with endocrine therapy.
